Overview and Scope
Viral vector manufacturing refers to producing viral vectors, tools that deliver genetic material into cells. A viral vector is a tool for gene transfer that can manipulate a particular cell type or tissue to express therapeutic genes.
Sizing and Forecast
The viral vector manufacturing market size has grown exponentially in recent years. It will grow from $5.82 billion in 2023 to $7 billion in 2024 at a compound annual growth rate (CAGR) of 20.4%. The growth in the historic period can be attributed to growth in pipeline of gene therapies, clinical success and approvals, increased investment in biopharmaceuticals, increased prevalence of genetic disorders.
The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $14.55 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to expanding applications in oncology, global collaborations in gene therapy research, adoption of viral vectors in vaccine development, continued clinical trials and commercialization. Major trends in the forecast period include technological innovations in vector production, emergence of next-generation vectors, regulatory compliance and standardization, collaborations and partnerships, global expansion of manufacturing facilities.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report
Segmentation & Regional Insights
The viral vector manufacturing market covered in this report is segmented –
1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users
North America was the largest region in the viral vector manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp
Major Driver Impacting Market Growth
The increase in the prevalence of cancer and infectious diseases is expected to propel the growth of the viral vector manufacturing market going forward. An infectious disease refers to a condition brought on by a virus or its toxic byproduct and spread to a susceptible host via contact with an infected person, animal, or item. Cancer refers to a broad range of illnesses that can develop in any organ or tissue of the body when aberrant cells grow out of control, cross their usual boundaries to invade neighbouring organs, and spread to other organs. Tumor antigens, or proteins on tumor cells, are produced via viral vectors to elicit the body’s anticancer immune response. In pre-clinical and clinical trials, viral vectors have served as vaccines against various infectious illnesses. For instance, in May 2022, according to the World Health Organization, a Switzerland-based specialized health agency, compared to 245 million cases in 2020, there were 247 million cases of malaria in 2021. Furthermore, in June 2023, according to the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, there were 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. Therefore, the increase in the prevalence of cancer and infectious diseases is driving the growth of the viral vector manufacturing market.
Key Industry Players
Major companies operating in the viral vector manufacturing market report are Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC,Oxford Biomedica plc, REGENXBIO Inc., LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.
The viral vector manufacturing market report table of contents includes:
1. Executive Summary
- Viral Vector Manufacturing Market Characteristics
- Viral Vector Manufacturing Market Trends And Strategies
- Viral Vector Manufacturing Market – Macro Economic Scenario
- Global Viral Vector Manufacturing Market Size and Growth
.
- Global Viral Vector Manufacturing Market Competitive Benchmarking
- Global Viral Vector Manufacturing Market Competitive Dashboard
- Key Mergers And Acquisitions In The Viral Vector Manufacturing Market
- Viral Vector Manufacturing Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
